131 related articles for article (PubMed ID: 23684582)
1. Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.
Lum E; Vigliotti M; Banerjee N; Cutter N; Wrzeszczynski KO; Khan S; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
Gynecol Oncol; 2013 Aug; 130(2):369-76. PubMed ID: 23684582
[TBL] [Abstract][Full Text] [Related]
2. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis.
Li Y; Hu W; Shen DY; Kavanagh JJ; Fu S
Am J Obstet Gynecol; 2009 Feb; 200(2):177.e1-9. PubMed ID: 19110234
[TBL] [Abstract][Full Text] [Related]
4. Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells.
Gupta N; Xu Z; El-Sehemy A; Steed H; Fu Y
Gynecol Oncol; 2013 Jul; 130(1):200-6. PubMed ID: 23542683
[TBL] [Abstract][Full Text] [Related]
5. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.
Fang F; Cardenas H; Huang H; Jiang G; Perkins SM; Zhang C; Keer HN; Liu Y; Nephew KP; Matei D
Cancer Res; 2018 Feb; 78(3):631-644. PubMed ID: 29229600
[TBL] [Abstract][Full Text] [Related]
6. FAU regulates carboplatin resistance in ovarian cancer.
Moss EL; Mourtada-Maarabouni M; Pickard MR; Redman CW; Williams GT
Genes Chromosomes Cancer; 2010 Jan; 49(1):70-7. PubMed ID: 19830698
[TBL] [Abstract][Full Text] [Related]
7. [Combinative effects of FAP-1 antisense oligonucleotide and carboplatin on apoptosis of ovarian cancer cell SKOV3].
Wang B; Zheng WG; Xin XY; Qi RY; Yu YC; Cao YX
Ai Zheng; 2004 Aug; 23(8):885-9. PubMed ID: 15301708
[TBL] [Abstract][Full Text] [Related]
8. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
Macleod K; Mullen P; Sewell J; Rabiasz G; Lawrie S; Miller E; Smyth JF; Langdon SP
Cancer Res; 2005 Aug; 65(15):6789-800. PubMed ID: 16061661
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
[TBL] [Abstract][Full Text] [Related]
10. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract][Full Text] [Related]
11. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
15. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
16. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M
Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852
[TBL] [Abstract][Full Text] [Related]
17. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
18. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients.
Flick MB; O'Malley D; Rutherford T; Rodov S; Kamsteeg M; Hao XY; Schwartz P; Kacinski BM; Mor G
J Soc Gynecol Investig; 2004 May; 11(4):252-9. PubMed ID: 15120700
[TBL] [Abstract][Full Text] [Related]
20. Dok2 likely down-regulates Klf1 in mouse erythroleukemia cells.
Tanaka Y; Kulkeaw K; Inoue T; Tan KS; Nakanishi Y; Shirasawa S; Sugiyama D
Anticancer Res; 2014 Aug; 34(8):4561-7. PubMed ID: 25075100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
